NASDAQ: PGNYProgyny Inc Stock
$21.44+0.04 (+0.19%)
Updated Apr 17, 2025
PGNY Price
$21.44
Fair Value Price
N/A
Market Cap
$1.83B
52 Week Low
$13.39
52 Week High
$33.84
P/E
36.34x
P/B
4.34x
P/S
1.35x
PEG
1.9x
Dividend Yield
N/A
Revenue
$1.17B
Earnings
$54.34M
Gross Margin
21.7%
Operating Margin
7.13%
Profit Margin
4.7%
Debt to Equity
0.44
Operating Cash Flow
$179M
Beta
1.13
Next Earnings
May 7, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PGNY Overview
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PGNY's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
B
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
PGNY
Ranked#6 of 44
Ranked#6 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $149.00 | A | |
| $62.37 | A | |
| $1.42 | B |
Be the first to know about important PGNY news, forecast changes, insider trades & much more!
PGNY News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PGNY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PGNY ($21.44) is trading above its intrinsic value of $7.12, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PGNY is poor value based on its earnings relative to its share price (36.34x), compared to the US market average (27.98x)
P/E vs Market Valuation
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PGNY due diligence checks available for Premium users.
Valuation
PGNY fair value
Fair Value of PGNY stock based on Discounted Cash Flow (DCF)
Price
$21.44
Fair Value
$5.99
Overvalued by
258.16%
PGNY ($21.44) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PGNY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
36.34x
Industry
11.14x
Market
27.98x
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PGNY is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
PGNY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.34x
Industry
3.39x
PGNY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PGNY price to earnings growth (PEG)
For valuing profitable companies with growth potential
PGNY is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
PGNY's financial health
Profit margin
Revenue
$298.4M
Net Income
$10.5M
Profit Margin
3.5%
PGNY's Earnings (EBIT) of $83.20M... subscribe to Premium to read more.
Interest Coverage Financials
PGNY's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$607.1M
Liabilities
$185.0M
Debt to equity
0.44
PGNY's short-term assets ($472.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PGNY's short-term assets ($472.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PGNY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PGNY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$52.2M
Investing
$75.0M
Financing
-$56.3M
PGNY's operating cash flow ($179.11M)... subscribe to Premium to read more.
Debt Coverage Financials
PGNY vs Health Information Service Stocks
Progyny Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.